<DOC>
	<DOCNO>NCT02931045</DOCNO>
	<brief_summary>Platelet activation aggregation lead myocardial infarction . Platelet P2Y12 receptor essential platelet activation . Antagonists P2Y12 receptor , establish secondary prevention myocardial infarction , unexplained anti-inflammatory effect . A novel P2Y12 receptor antagonist ticagrelor reduce infection-related mortality compare clopidogrel , previous standard treatment patient myocardial infarction . Activated platelet release pro-inflammatory procoagulant platelet extracellular vesicle . The investigator assume decrease infection-related mortality patient treat ticagrelor may explain great inhibition release platelet vesicle ticagrelor , compare clopidogrel . This study expect identify additional mechanism action ticagrelor , might contribute observed clinical benefit patient treat ticagrelor .</brief_summary>
	<brief_title>Antiplatelet Therapy Effect Platelet Extracellular Vesicles Acute Myocardial Infarction</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Blister</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Age &gt; 18 year Informed consent participate study Percutaneous coronary intervention stent implantation due first STelevation myocardial infarction , first non STelevation myocardial infarction Administration load dose clopidogrel Known coagulopathy Known history bleed disorder Suspicion intracranial haemorrhage Need oral anticoagulation therapy Administration glycoprotein ( GP ) IIbIIIa antagonists Cardiogenic shock Severe chronic renal failure ( estimate glomerular filtration rate [ eGFR ] &lt; 30 mL/min ) Severe liver insufficiency Chronic dyspnea Increased risk bradycardia Autoimmune disease Infectious disease Neoplasms Pregnancy Study drug intolerance Coadministration ticagrelor clopidogrel strong CYP3A4 inhibitor Participation previous study ticagrelor clopidogrel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>extracellular vesicle</keyword>
	<keyword>inflammation</keyword>
	<keyword>thrombosis</keyword>
	<keyword>antiplatelet drug</keyword>
</DOC>